Dr. George-Daniel Radavoi

Competente in:

• Urologie laparoscopica si robotica
• Litotritie extracorporeala
• Ultrasonografie generala

Afilieri:

• Colegiul Medicilor din Romania
• Asociatia Romana de Urologie
• Asociatia Europeana de Urologie

• 2016: Doctor in Stiinte Medicale, Universitatea de Medicina si Farmacie "Carol Davila", Bucuresti
• 2013: Protectia radiologica in radiologia de diagnostic si in radiologia interventionala, Scoala Nationala de Sanatate Publica, Management si Perfectionare in Domeniul Sanitar Bucuresti

Activitate didactica:

• 2022 - prezent: Conferentiar Universitar, Universitatea de Medicina si Farmacie "Carol Davila", Bucuresti
• 2018 - 2022: Sef Lucrari, Universitatea de Medicina si Farmacie "Carol Davila", Bucuresti
• 2012 - 2018: Asistent universitar, Universitatea de Medicina si Farmacie "Carol Davila", Bucuresti

Conferinte si seminare:

• 2019 - 2021:
  • ROMURO, Congres Online
• 2019:
  • 2019 Annual Meeting of the AUA, Chicago, USA
  • 34th Annual EAU Congress, Barcelona, Spania
  • 19th Central European Meeting, Viena, Austria
• 2018:
  • 18th Central European Meeting, Cluj Napoca
  • ROMURO, Cluj Napoca
• 2017:
  • 32nd Annual EAU Congress London, Londra, Regatul Unit
• 2016:
  • 16th Central European Meeting, Viena, Austria
  • Urologic Surgery Clinical Immersion training, Belinson-Rabin Medical Center, Affiliated with Sacker School of Medicine, Tel Aviv University, Tel Aviv, Israel
• 2015:
  • 15th EAU Central European Meeting, Budapesta, Ungaria
  • Locally advanced prostate cancer and non-muscle invasive bladder cancer, European School of Urology, Bucuresti
• 2014:
  • Minimally Invasive Techniques for Laparoscopic Pelvic Surgery, Delta Endoscopic Training Center, Bucuresti
  • Minimally invasive treatment of renal stones, European School of Urology, Bucuresti
  • Nefrolitotritia Percutanata, Universitatea de Medicina si Farmacie "Victor Babes" Timisoara
• 2013:
  • ESU Course on the placement and role of lymphadenectomy in urologic cancers, European School of Urology, Bucuresti
• 2012:
  • Oncology (TCC & Adrenal) &Teaching Techniques, American Urological Association, Atlanta, USA
  • Robot-Assisted Surgery: Advances in Oncology, Image Guidance and Reconstruction, American Urological Association, Atlanta, USA
• 2010:
  • Stone surgery, lower urinary tract, prostate cancer and paediatric urology, European School of Urology Course, Bucuresti
• 2009:
  • Upper Tract, invasive bladder and penile cancer, European School of Urology Course, Bucuresti
• 2008:
  • Olympus Hands-On-Training dry lab course on laparoscopy, European School Of Urology, Praga, Cehia
  • 6th Course, European Urology Residents Education Programme, Praga
  • Urinary lithiasis, European School of Urology Course, Bucuresti
  • Kidney cancer, European School of Urology Course, Bucuresti
• 2005:
  • Recent aspects of prostate cancer, European School of Urology, Bucuresti
  • Recent aspects of Urolithiasis, European School of Urology, Bucuresti

• 2011: 
  
  • Atestat in "Litotritie extracorporeal", Universitatea de Medicina si Farmacie "Carol Davila", Bucuresti
  • Atestat in "Ultrasonografie generala", Universitatea "Lucian Blaga" Sibiu

Proiecte:

• 2018 - 2021: 
  • Mutographs of cancer: discovering the causes of cancer through mutational signatures, WHO Research
• 2013 - 2017:
  • Team leader - Epidemiologia genetica a cancerului in Romania, Universitatea de Medicina si Farmacie "Carol Davila", Bucuresti
• 2011 - 2014:
  • Director proiect - Comparatie intre biopsia prostatica sistematica si cea tintita ultrasonografic cu ajutorul substantei de contrast la pacientii aflati in tratament cu inhibitori de 5-alfa reductaza, Universitatea de Medicina si Farmacie "Carol Davila", Bucuresti
• 2007 - 2013:
  • Membru echipa de cercetare - Genetic prostate cancer variants as biomarkers of disease progression, deCODE Genetics (Islanda)

Studii clinice internationale:

• 2018 - prezent: 
  • Sub-investigator in studiul de faza III cu protocolul 204989, Phase III, Double-Blind, Parallel-Group, Comparator-Controlled, Efficacy and Safety Study of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
• 2015 - prezent:
  • Sub-investigator in studiul de faza III cu protocolul B9991003,  A Phase 3, Multinational, Randomized, Open-Label, parallelarm study of avelumab (Msb0010718c) in combination with Axitinib (Inlyta®) Versus Sunitinib (Sutent®) Monotherapy in the first-line treatment of patients with advanced renal cell carcinoma
  • Sub-investigator in studiul de faza III cu protocolul 9785-CL-0335, Studiu multinational, de faza 3, randomizat, dublu-orb, controlat placebo, privind eficacitatea si siguranta enzalutamidei in combinatie cu terapia de privare de androgeni (ADT) comparativ cu placebo in combinatie cu ADT la pacienti cu cancer de prostata metastatic hormono-sensibil (mHSPC)
• 2011 - prezent:
  • Sub-investigator in studiul de faza lb/II cu protocolul GO27983, A Phase Ib/II Study of GDC-0068 or GDC-0980 with Abiraterone Acetate versus Abiraterone Acetatein Patients with Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
• 2018 - 2021:
  • Sub-investigator in studiul de faza III cu protocolul VNRX-5133-201, A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis
• 2018 - 2020:
  • Sub-investigator in studiul de faza III in studiul SPR994-301, A Phase 3, Randomized, Double blind,Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)”
• 2016 - 2018: 
  • Sub-investigator in studiul de faza III cu protocolul TP-434-021, Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections
• 2016:
  • Sub-investigator in studiul de faza III cu protocolul ACHN-490-009, A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Meropenem followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), including Acute Pyelonephritis (AP), in Adults
• 2015 - 2018:
  • Sub-investigator in studiul de faza III cu protocolul AQX-1125-301, The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel- Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2- containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period
• 2014 - 2017:
  • Sub-investigator in studiul de faza III cu protocolul 1409R2121, Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison with Intravenous Imipenem/Cilastatin
• 2013 - 2015:
  • Sub-investigator in studiul de faza III cu protocolul TP-434-010, A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated Urinary Tract Infections
• 2013 - 2021:
  • Sub-investigator in studiul de faza III cu protocolul 3104007, MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.
• 2012 - 2015:
  • Sub-investigator in studiul de faza II cu protocolul 7035-CL-0014, A Phase II, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio of ASP7035 in Patients With Nocturia Associated With Nocturnal Polyuria
• 2012 - 2013:
  • Sub-investigator in studiul de faza III cu protocolul ITCL0414, Efficacy and safety of a single TRUS-guided intraprostatic injection of NX-1207 in patients with Lower Urinary Tract Symptoms associated with Benign Prostatic Hyperplasia: a phase III European clinical study
• 2011 - 2014:
  • Sub-investigator in studiul AstraZeneca de faza III cu protocolul D4280C00006, An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram-Negative Pathogens

Premii/distinctii internationale:

• 2017:
  • First Berlin Chemie Award for Best Poster Presentation. "Genetic biomarkers related with prostate cancer: New perspectives" Sandu B.S, Jinga V., Dragomiristeanu I., Codreanu O., Nedelea S., Persu C., Radavoi D. EAU 17 Central European Meeting, Plzen
• 2016:
  • First Berlin Chemie Award for Best Poster Presentation. "Genomic aspects regarding prostate cancer aggressiveness". B. Cheorpeaca, V. Jinga, O. Codreanu, D. Radavoi, D. Badescu, R. Petca. EAU 16th Central European Meeting, Viena, Austria
• 2015:
  • First Prize for the Young Urologists Competition. "New genetic perspectives in prostate and renal cancer" at the EAU 15 Central European Meeting, Budapesta, Ungaria
• 2014:
  • First Berlin Chemie Award for Best Poster Presentation. "Genetic studies on Romanian prostate cancer patients confirm genetic risk variants for prostate cancer". A.S.C. Rascu, V. Jinga, M. Dumitrache, M. Merticariu, R. Petca, D. Radavoi, D. Badescu, EAU 14th Central European Meeting, 2014, Cracovia, Polonia

Publicatii:

• UROLOGIE PENTRU VIITORII CHIRURGI SI GINECOLOGI ISBN:978-606-13-6131-1. AUTORI: CATALIN PRICOP, VIOREL JINGA, ALIN CUMPANAS
• CURS ACADEMIC PENTRU ASISTENTI MEDICALI Ed. Pim 2018 – ISBN: 978-606-13-4549-6. AUORI: CATALIN PRICOP, DRAGOŞ PUIA, DANIEL RADAVOI, ADELINA MIRON, IRINA NEGRU - COAUTOR
• APARATURA SI DISPOZITIVE MEDICALE Ed. Carol Davila 2012 – ISBN: 978-973708-633-4 COORDONATOR: PROF. UNIV. DR. CONF. UNIV. DR. VICTOR LORIN PURCAREA CAPITOLUL XI – Echipamente de urologie
• Determining whether previous SWL for ureteric stones influences the results of ureteroscopy as the secondline treatment: A clinical study. Pricop C, Ivanuta M, Radavoi GD, Toma CV, Cumpanaş A, Jinga V, Bacalbaşa N, Puia D. Determining whether previous SWL for ureteric stones influences the results of ureteroscopy as the second-line treatment: A clinical study. Exp Ther Med. 2022 Jan;23(1):38. doi: 10.3892/etm.2021.10960. Epub 2021 Nov 11. PMID: 34849153; PMCID: PMC8613534
• Levofloxacin versus Cefixime as an empiric treatment in acute bacterial prostatitis. Catalin Pricop, Dragos Puia, Daniel Andone, Silviu Latcu , George Daniel Radavoi, Ioan Cordos, Viorel Jinga, Tudor Proca, Alin Cumpanas. Levofloxacin versus Cefixime as an empiric treatment in acute bacterial prostatitis. Farmacia, 2021, Vol. 69, 4: 682-687
• Antihypertensive drugs and blood pressure variability. Adriana-Mihaela Iliesiu, Ioan Cordos, Irina Parvu, Ioana Verde, Andreea Stela Liteanu, Andreea Simona Hodorogea , George Daniel Radavoi. Antihypertensive drugs and blood pressure variability. Farmacia, 2021, Vol. 69, 2: 200-207
• Correlations between stones composition, dietary and comorbidities context of the lithiasic patient. Pricop C, Ivanuta M, Stan A, Anton-Paduraru DT, Radavoi GD, Jinga V, Proca TM, Puia D. Correlations between stones composition, dietary and comorbidities context of the lithiasic patient. Rom J Morphol Embryol. 2020 Oct-Dec;61(4): 1227-1233. doi: 10.47162/RJME.61.4.24. PMID: 34171071; PMCID: PMC8343589
• Antibiotic prophylaxis in transurethral resections: what are the criteria that should be followed?. Catalin Pricop, Ligia Florentina Furtunescu, Daniel Radavoi*,Viorel Jinga, Alin Cumpanas, Dana-Teodora Anton-Paduraru, Adelina Miron, Cristian Toma, Dragos Puia. Antibiotic prophylaxis in transurethral resections: what are the criteria that should be followed? Farmacia, 2020, Vol. 68, 6: 1021-1028
• The Complex Context of the Involvement of Vitamin D Deficiency in Obesity. Stanescu AMA, Grajdeanu IV, Totan A, Miricescu D, Serban B, Buhas CL, Radavoi DG. The Complex Context of the Involvement of Vitamin D Deficiency in Obesity. Rev. Chim.[internet]. 2019 Oct;70(10):3654-3656.
• Obesity and its Implications on Stress Urinary Incontinence. Dumitrascu MC, Stanescu AMA, Bejan C, Sandru F, Toader DO, Radavoi DG, Cotirlet A, Pusta CTJ, Diaconu CC. Obesity and its Implications on Stress Urinary Incontinence. Rev. Chim.[internet]. 2019 Oct;70(10):3660-3662.
• Obesity: a delicate issue choosing the eswl treatment for patients with kidney and ureteral stones?. Pricop C, Radavoi GD, Puia D, Vechiu C, Jinga V. Obesity: a delicate issue choosing the eswl treatment for patients with kidney and ureteral stones? Acta Endocrinol (Buchar). 2019 Jan-Mar;-5(1):133-138.. PMID: 31149074; PMCID:PMC6535322
• Immunohistochemistry Particularities of Retroperitoneal Tumors. Radavoi GD, Pricop C, Jinga V, Mates D, Radoi VE, Jinga M, Ursu RI, Bratu OG, Mischianu DL, Iordache P. A comprehensive analysis of genome-wide association studies to identify prostate cancer susceptibility loci for the Romanian population. Rom J Morphol Embryol. 2016;57(2):467-75
• Infected hydronephrosis: can we reduce patient suffering and costs?. Catalin Pricop, Dragos Puia, Oleg Mereuta, Catalin Ciuta, Liviu Todosi, Martha Orsolya,George Daniel Radavoi. Infected hydronephrosis: can we reduce patient suffering and costs? J Pak Med Assoc. 2016 Nov;66(11):1372 1377